Author Topic: Seletalisib Phase II Trial published  (Read 404 times)

markt

  • Full Member
  • ***
  • Posts: 214
Seletalisib Phase II Trial published
« on: November 18, 2019, 11:26:30 AM »
No longer relegated to being studied in murine models...

https://ard.bmj.com/content/78/Suppl_2/1692.2

Seletalisib is a potent, selective oral inhibitor of phosphoinositide-3 kinase delta (PI3Kδ). Preclinical data have shown that the PI3Kδ pathway is upregulated within salivary glands of patients with PSS and contributes to disease pathogenesis.   

https://clinicaltrials.gov/ct2/show/NCT02610543

https://sjogrenssyndromenews.com/2019/01/15/seletalisib-improves-saliva-flow-lowers-inflammation/

It will be interesting to see what happens in lager Phase-III trials...
« Last Edit: November 18, 2019, 11:33:42 AM by markt »